Fig. 6. PFCE-C25 NEs inhibit LLC tumor growth by activating CD8⁺ T cells, reducing FOXP3⁺ T_regs, and increasing proinflammatory cytokine production.

(A) CD8⁺ T cell and CD4⁺ T cell infiltration in tumors (n = 4), spleens (n = 3), and TDLNs (n = 3). (B) FOXP3⁺ T_reg infiltration in tumors of each treatment group (n = 3). (C) Ratios of CD8⁺ IFN-γ⁺ T cells and CD4⁺ IFN-γ⁺ T cells in tumors (n = 6), spleens (n = 3), and TDLNs (n = 3) of each treatment group. (D) Levels of IFN-γ⁺, IL-6, IL-12, and TNF-α in tumors. (E) The levels of IFN-γ⁺, IL-6, IL-12, and TNF-α in serum of each treatment group were verified by ELISA (n = 4). The data are presented as the mean ± SD.